Therapeutic target identification and validation for MASLD via patient transcriptome-driven in vivo genetic screening
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is rising in prevalence over the years but current treatments such as Resmetirom are inadequate as remedy for most MASLD patients. With scarce liver sources available, liver regeneration offers a more sustainable approac...
Saved in:
Main Author: | Lee, Yi Jing |
---|---|
Other Authors: | Torsten Wuestefeld |
Format: | Final Year Project |
Language: | English |
Published: |
Nanyang Technological University
2024
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/181532 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Patient transcriptomic based in vivo functional genetic dissection of NAFLD for therapeutic target identification
by: Moo, Jia Rong
Published: (2023) -
Insights into gender-specific differences in MASLD hepatic transcriptomes
by: Chan, Sook Teng
Published: (2023) -
The LIDPAD mouse model captures the multisystem interactions and extrahepatic complications in MASLD
by: Low, Zun Siong, et al.
Published: (2024) -
Genetic validation of PfFKBP35 as an antimalarial drug target
by: Thommen, Basil T., et al.
Published: (2024) -
Identification and validation of novel therapeutic targets in mast cell mediated allergic responses
by: JAYAPAL MANIKANDAN
Published: (2011)